Biogen's pipeline has faced setbacks, including the discontinuation of SAGE-324 for essential tremor following disappointing Phase 2 results. However, the company maintains several promising ...
Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...
Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...
With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...
Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet ...
In Wednesday’s 2024 full-year earnings, the Cambridge drugmaker gave more details on cuts to its early-stage pipeline. Biogen said it would discontinue further development of certain programs in ...
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal Vandana Singh Tue, Feb 18, 2025, 1:32 PM 2 min read ...
As part of ongoing pipeline prioritization efforts, Biogen has decided to discontinue further development of BIIB113 in early Alzheimer’s disease, BIIB094 in early Parkinson’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results